Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Paraproteinemias 1Neoplasms, Plasma Cell 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 8Rituximab 5fludarabine 4Vincristine 4Prednisone 4Doxorubicin 4fludarabine phosphate 3Tacrolimus 3Mycophenolic Acid 3Etoposide 3Busulfan 3venetoclax 2entrectinib 2atezolizumab 2alectinib 2acalabrutinib 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Bortezomib 2trametinib 1pertuzumab 1pembrolizumab 1obinutuzumab 1liposomal doxorubicin 1isatuximab 1ibrutinib 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Chromatin Immunoprecipitation Sequencing × 1 year × Clear all
NCT06630104 2026-01-08

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Mayo Clinic

Phase NA Recruiting
82 enrolled
LymphoidPlasma cell

Lymphoproliferative Disorders, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡